ATRO Medical closed a €3 million (~USD $3.5 million) financing round. The company has reached a milestone in the clinical evaluation of its latest Artimis Meniscus Prosthesis design; ongoing studies are designed to further assess the artificial meniscus system in patients experiencing persistent knee pain following meniscus removal.
In addition to its clinical progress, ATRO Medical has strengthened its intellectual property position and gained international traction by its selection for the PlugAndPlay Health incubator in the U.S., positioning the company for the next phase of growth.
The newly-secured capital will be used to expand clinical evidence generation in ongoing studies, prepare the company for the pivotal clinical trial in the United States and Europe, and further optimize manufacturing, regulatory readiness, and clinical operations.
Michiel Schwartz, Chairman of the Board of ATRO Medical, said, “This investment reflects strong international confidence in ATRO Medical’s technology, team and strategy. The recent clinical outcomes confirm that we have cracked the code for patients with post-meniscectomy pain. With this experienced leadership team and a clear path toward pivotal studies in the US and Europe, ATRO Medical is entering a defining phase in its development.”
ATRO Medical closed a €3 million (~USD $3.5 million) financing round. The company has reached a milestone in the clinical evaluation of its latest Artimis Meniscus Prosthesis design; ongoing studies are designed to further assess the artificial meniscus system in patients experiencing persistent knee pain following meniscus removal.
In...
ATRO Medical closed a €3 million (~USD $3.5 million) financing round. The company has reached a milestone in the clinical evaluation of its latest Artimis Meniscus Prosthesis design; ongoing studies are designed to further assess the artificial meniscus system in patients experiencing persistent knee pain following meniscus removal.
In addition to its clinical progress, ATRO Medical has strengthened its intellectual property position and gained international traction by its selection for the PlugAndPlay Health incubator in the U.S., positioning the company for the next phase of growth.
The newly-secured capital will be used to expand clinical evidence generation in ongoing studies, prepare the company for the pivotal clinical trial in the United States and Europe, and further optimize manufacturing, regulatory readiness, and clinical operations.
Michiel Schwartz, Chairman of the Board of ATRO Medical, said, “This investment reflects strong international confidence in ATRO Medical’s technology, team and strategy. The recent clinical outcomes confirm that we have cracked the code for patients with post-meniscectomy pain. With this experienced leadership team and a clear path toward pivotal studies in the US and Europe, ATRO Medical is entering a defining phase in its development.”
Copy to clipboard 
